Combination therapy with cisplatin: modulation of activity and tumour sensitivity.
Although cisplatin is applied with success in clinical oncology, this success is limited because some cancers are initially unresponsive to cisplatin or become so during treatment. In this review, some strategies to overcome this problem are discussed. Among these are combination with the differentiation inducing agent, retinoic acid, combination with radiotherapy, and the use of hyperthermia.
Guchelaar
H J
HJ
Department of Pharmacy and Toxicology, University Hospital, Groningen, The Netherlands.
Uges
D R
DR
de Vries
E G
EG
Oosterhuis
J W
JW
Mulder
N H
NH
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D006801:Humans; D006979:Hyperthermia, Induced; D009369:Neoplasms / Q000188:drug therapy*; D011878:Radiotherapy; D014212:Tretinoin / Q000008:administration & dosage
D014212:Tretinoin; D002945:Cisplatin